Skip to main content

Table 2 Demographic data, clinical features and biomarker findings in each enrolled patient. The table shows patients’ findings according to the biomarkers (n. 26 with FDG-PET data and amyloid measures, either by amyloid-PET study or CSF assessment; n.4 with FDG-PET data)

From: A biomarker study in long-lasting amnestic mild cognitive impairment

 

Gender

Age

Education

MMSE at the first evaluation

Diagnosis at the first evaluation

Disease duration at the first evaluation

MMSE at the follow-up

Diagnosis at the follow-up

Disease duration at the follow-up

FDG-PET pattern

Amyloid-PET neocortical SUVr values

CSF Aβ42

CSF t-Tau

CSF p-Tau

t-Tau/ Aβ42 Ratio

#1

F

79

17

26

s-aMCI

26

24

s-aMCI

81

C

1.38

752

222

45

0.29

#2

M

77

6

28

s-aMCI

48

27

s-aMCI

145

C

1.16

957

243

35

0.25

#3

M

71

13

29

m-aMCI

108

28

m-aMCI

163

B

1.15

630

122

30

0.19

#4

M

83

17

24

m-aMCI

36

22

m-aMCI

118

C

1.09

1000

505

71

0.50

#5

M

75

5

23

m-aMCI

60

25

m-aMCI

119

C

1.18

720

174

35

0.24

#6

M

72

13

27

s-aMCI

72

28

s-aMCI

127

B

1.63

255

352

82

1.38

#7

M

79

18

25

s-aMCI

72

23

m-aMCI

115

C

1.90

252

293

73

1.16

#8

M

68

8

29

s-aMCI

36

25

m-aMCI

91

B

1.44

400

275

52

0.68

#9

M

70

5

25

s-aMCI

48

26

m-aMCI

115

B

1.21

411

638

102

1.55

#10

M

84

13

28

m-aMCI

96

22

m-aMCI

151

C

1.59

596

171

39

0.28

#11

M

77

11

25

s-aMCI

48

25

s-aMCI

103

B

1.66

-

-

-

-

#12

M

69

8

27

s-aMCI

36

26

s-aMCI

83

B

1.69

-

-

-

-

#13

F

71

12

24

s-aMCI

24

25

s-aMCI

79

C

1.83

-

-

-

-

#14

F

69

8

29

m-aMCI

24

22

m-aMCI

79

C

1.71

-

-

-

-

#15

M

77

3

24

m-aMCI

36

23

m-aMCI

91

C

1.19

-

-

-

-

#16

F

76

5

27

m-aMCI

60

26

m-aMCI

115

C

1.59

-

-

-

-

#17

M

71

18

28

s-aMCI

24

28

s-aMCI

79

A

-

742

259

42

0.34

#18

F

69

17

27

s-aMCI

108

26

m-aMCI

175

A

-

270

339

70

1.25

#19

F

65

8

28

s-aMCI

24

27

m-aMCI

85

B

-

497

489

105

0.98

#20

F

68

5

25

m-aMCI

60

23

m-aMCI

118

B

-

365

343

59

0.94

#21

M

76

8

27

m-aMCI

18

26

m-aMCI

73

B

-

734

268

45

0.36

#22

F

80

10

26

m-aMCI

24

21

m-aMCI

91

A

-

355

763

108

2.15

#23

M

78

13

29

m-aMCI

24

27

m-aMCI

73

C

-

1010

379

87

0.37

#24

M

71

8

28

m-aMCI

24

26

m-aMCI

79

B

-

308

886

134

2.87

#25

M

77

13

29

m-aMCI

60

28

m-aMCI

123

C

-

847

379

84

0.45

#26

F

75

12

24

m-aMCI

24

23

m-aMCI

79

A

-

454

244

48

0.54

#27

F

73

5

25

s-aMCI

50

25

s-aMCI

79

C

-

-

-

-

-

#28

M

79

13

28

s-aMCI

120

27

s-aMCI

83

C

-

-

-

-

-

#29

F

69

13

29

s-aMCI

60

27

m-aMCI

87

C

-

-

-

-

-

#30

F

76

5

21

m-aMCI

52

21

m-aMCI

85

B

-

-

-

-

-

  1. MMSE Mini Mental State Examination; CSF cerebrospinal fluid; Aβ42 β Amyloid (1-42) protein; t-Tau total tau; p-Tau phosphorylated tau; M male; F female; s-aMCI single-domain amnestic Mild Cognitive Impairment; m-aMCI multiple domain amnestic Mild Cognitive Impairment; FDG-PET pattern A selective hypometabolism of medial temporal lobe structures (hippocampus and/or hippocampal structures); FDG-PET pattern B hypometabolism of medial temporal lobe structures and posterior cingulate cortex; FDG-PET pattern C extensive hypometabolism involving medial temporal lobe structures and other fronto-limbic structures
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193